

Composition:

Each ml contains:

Ambroxol HCl 7.5mg

Mechanism of Action

KOFAREST DROPS is a preparation of Ambroxol hydrochloride. Ambroxol has secret motor with secretolytic effects. It stimulates serous cells of gland of bronchial mucous membranes, increases mucous secretion content by changing the structure of bronchial secretion. Thus results in reduction of expectoration viscosity by reducing and fragmenting mucopolysaccharide fibers. It also intensifies motion of ciliated epithelium or cilia, increasing expectoration transport. KOFAREST DROPS stimulates synthesis of phospholipids by alveolar cells and formation of surfactant lipids. It clearly improves breathing and suppresses coughing to some extent.

Indication:

A Kofarest drop is indicated for the treatment of

- Acute and Chronic infections of the respiratory tract associated with abnormal secretions, such as-
 - ✓ Acute bronchitis
 - ✓ Acute exacerbations of chronic bronchitis
 - ✓ Asthmatic bronchitis
 - ✓ Bronchiectasis
 - ✓ Bronchial asthma
 - ✓ Chronic pneumonia
- Inflammatory diseases of the rhino pharyngeal tract, like-
 - ✓ Laryngitis
 - ✓ Pharyngitis
 - ✓ Sinusitis
 - ✓ Rhinitis

Contraindication:

Kofarest drops are contraindicated in patients with

- Hypersensitivity to any ingredient of the formulation.
- Gastroduodenal ulcer.

Drug Interaction:



No specific drug interactions noted.

Adverse effects:

KOFAREST DROPS are well tolerated; however, rarely allergic responses such as skin eruption, urticaria or angioneurotic edema may occur. While used for a long time, epigastric pain, stomach overfill feeling cannot be excluded.

Warnings and Precautions:

If there is any problem related to kidney or liver, consultation with the prescriber is needed.

Use in special population:

- 1. Pediatric: Safe in children.
- 2. Geriatric: Clinical studies of did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects. If clinically warranted due to insufficient bronchodilator response, the dose of may be increased in elderly patients as tolerated, in conjunction with frequent clinical and laboratory monitoring, to the maximum recommended daily dose.
- 3. Liver impairment: Use with caution.
- 4. Renal failure: Use with caution.
- **5. Pregnancy and lactation:** Safety of Ambroxol in pregnancy has not yet been established. The usual precaution regarding the use of drugs at this time, especially during the first trimester should be observed. Safety during lactation has not yet been established.

Dosage:

KOFAREST DROPS are recommended after meals.

- Children under 6 months: 0.5 ml twice daily
- Children 7 to 12 months: 1 ml thrice daily.
- Children 13 to 24 months: 2 ml 2-3 times daily or as directed by physician.

The drops can be given diluted with fruit juice, milk or water.

Presentation:

KOFAREST DROPS are available in 15 ml pack with dropper.

Storage and handling:

KOFAREST DROPS should be kept away from light, store in a cool (below 30OC) and dry place. Keep out of reach of children.

